Revelation Biosciences Inc. provided a corporate update reflecting on achievements in 2025 and outlining plans for 2026. The company announced the successful completion of a Phase 1b clinical study in chronic kidney disease (CKD) patients, highlighting "game changing" results for its drug candidate Gemini, which demonstrated the ability to rebalance cellular inflammation. Looking ahead, management emphasized preparations for a later-stage clinical trial targeting acute kidney injury (AKI), including scaling up drug manufacturing, engaging clinical investigators, and partnering with a top-tier clinical research organization. The company is also preparing for a key meeting with the FDA to discuss regulatory and clinical development pathways for Gemini as a treatment for AKI. Revelation Biosciences stated it is in a strong financial position as it moves toward initiating a Phase 2 or Phase 3 AKI study in 2026.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Revelation Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001193125-25-306915), on December 03, 2025, and is solely responsible for the information contained therein.
Comments